Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report.

Journal of ovarian research - 8 Dec 2020

Lin Yu-Chien, Wen Kuo-Chang, Sung Pi-Lin, Chou Yu-Ting, Liew Phui-Ly, Chen Lin-Yu, Huang Rui-Lan, Lai Hung-Cheng, Chang Lu-Te

Abstract excerpt

BACKGROUND: Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed. CASE PRESENTATION: We present a patient with refractory OCCC in whom conventional chemotherapy failed. Cachexia was induced by the disseminating recurrent tumors. Tumor tissue staining and genomic analysis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to DNA-Binding Proteins

Share to Mutation

Share to Ovarian Neoplasms

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 33292376
DOI: 10.1186/s13048-020-00751-3
PMCID: PMC7725117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report.PMID 33292376Read ↗

Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature ReviewSemantic proximity Read ↗

Durable Disease Control after Sequential Anlotinib Maintenance Therapy Following Local Radiotherapy in a Patient with Platinum-Refractory Recurrent Ovarian Clear Cell Carcinoma: A Case Report and Literature ReviewSemantic proximity Read ↗

Translational genomics of ovarian clear cell carcinoma.Semantic proximity Read ↗

Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case report.Semantic proximity Read ↗

Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.Semantic proximity Read ↗

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

Ovarian clear cell adenocarcinoma: a continuing enigma.Semantic proximity Read ↗

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.Semantic proximity Read ↗

Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.Semantic proximity Read ↗

The target therapy of ovarian clear cell carcinomaSemantic proximity Read ↗

Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.Semantic proximity Read ↗

New therapies for clear cell ovarian carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.